Celgene appoints Dr David Gillen as its UK and Ireland medical director
pharmafile | January 9, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Celgene
Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director.
Gillen brings much experience to his new role after holding a number of leadership positions within pharma over the past decade.
Gillen worked as a doctor in the NHS for seven years before joining Pfizer’s R&D unit.
Following this, he held the position of medical director at Wyeth and subsequently Pfizer, and in 2010 joined Gilead Sciences as head of international medical affairs.
Gillen has worked closely with external stakeholders throughout his career, including NICE, and has been active in initiatives to improve collaboration between the NHS, academic medicine and industry.
He commented: “This is a very exciting time as Celgene’s portfolio expands and I can’t wait to build on the excellent work that’s already being undertaken.”
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …






